Zdravotníctvo
Atlantic Study Positions ZERIT(R) (d4T, Stavudine) and Once-Daily VIDEX(R) (ddI, didanosine) as Flexible, First-Line Foundation of HIV 'Cocktails'
SAN FRANCISCO (PROTEXT) - Landmark International Treatment'Strategy' Trial Results Provide Patients and Doctors ImportantNews on Customizing Treatment With Three Types of Anti- HIVCocktails According to preliminary 48-week data from the ATLANTIC...
Zadavatel:
XTL Biopharmaceuticals' Human Monoclonal Antibody Therapeutic For Chronic Hepatitis B Enters Phase I Clinical Trials / First Product Developed Using Company's P
REHOVOT, Israel (PROTEXT) - XTL Biopharmaceuticals, Ltd.announced today the initiation of a Phase I study of XTL001, aninvestigational monoclonal antibody (MAb) product, to evaluatethe safety profile and antiviral activity of the compound inchronically...
Zadavatel:
Long-term Results of First Head-to-Head Trial of a Triple Cocktail Regimen Involving the Three Classes of Antiretrovirals
INGELHEIM (ots-PRNewswire) - Data on VIRAMUNE(R) in DifferentTreatment Settings Presented at ICAAC Meeting Today researchers unveil the eagerly awaited 48-week resultsof the international, multicenter Atlantic trial -- the firsthead-to-head comparison...
Zadavatel:
New Study Shows Promising Results for Herceptin / Safety and Efficacy Demonstrated in Women With Advanced HER2- Positive Breast Cancer
BASEL, Switzerland (PROTEXT) - Women with advanced(metastatic) breast cancer who were treated with Herceptin(R)(trastuzumab) demonstrated long-lasting, significant response totherapy with almost none of the side effects commonly seen withconventional...
Zadavatel:
Quidel obdržel povolení FDA pro ordinační diagnostický test na chřipku / Chřipkový test QuickVue prvním krokem diagnostického a léčebného programu pro nemocné c
SAN DIEGO (USA) 27. září (PROTEXT/ots) - Quidel Corporation(Nasdaq: QDEL) dnes oznámila, že od Úřadu USA pro potraviny aléky (FDA) dostala povolení uvést na trh svůj Chřipkový testQuickVue(R), což je rychlý, v ordinacích aplikovatelnýdiagnostický test...
Zadavatel:
Mezinárodní zdravotnický tým dobrovolníků The Flying Hospital (Létající nemocnice) zahajuje cestu po Rusku; Bezplatná lékařská péče a chirurgické zákroky v pěti
MOSKVA 27. září (PROTEXT/PRNewswire) - Mezinárodnízdravotnický tým dobrovolníků - lékařů, zdravotních sester apomocného personálu - zahajuje dnes sedmitýdenní misi, v jejímžrámci zavítá do pěti ruských měst a poskytne vyspělou lékařskou achirurgickou...
Zadavatel:
ATL Ultrasound Announces Breakthrough in Medical Imaging With SonoCT(TM) Real-Time Compound Imaging
BOTHELL, Wash. (PROTEXT) - Most Important UltrasoundDevelopment in Years Expected To Significantly Aid Detection ofBreast Lesions In what is being described by leading radiologists as the mostimportant development in ultrasound in more than a decade,...
Zadavatel:
Heska Corporation Announces European Approval for PERIOceutic(TM) Gel
FORT COLLINS, Colo. (PROTEXT) - Heska Corporation (Nasdaq:HSKA), a leader in the companion animal health market, announcedtoday that its PERIOceutic(TM) Gel has been approved by theEuropean Commission for marketing and distribution in Europe. Theproduct...
Zadavatel:
Eisai and Pfizer: ARICEPT(R) (donepezil HCl) Maintains Functional Ability in The Majority of Alzheimer's Disease Patients on Therapy for One Year
LONDON (PROTEXT) - New Data from a One-Year U.S. StudyReinforces European Findings ARICEPT(R) (donepezil HCl) treatment significantly extends thefunctional ability of patients with mild to moderate Alzheimer'sdisease, according to new one-year data...
Zadavatel:
Bristol-Myers Squibb and Otsuka Announce Commercialization Agreement For Aripiprazole
PRINCETON, N.J., and TOKYO (PROTEXT) - -- Aripiprazole a Promising New Agent for Schizophrenia -- New Therapies Greatly Needed for Debilitating MentalIllness Bristol-Myers Squibb Company (NYSE: BMY) and OtsukaPharmaceutical Co., Ltd. announced today...
Zadavatel:
Rhone-Poulenc Rorer Pharmaceuticals Inc. Statement US FDA Approval of Synercid(R) (Quinupristin/Dalfopristin) I.V.
COLLEGEVILLE, Pa. (PROTEXT) - The following statement wasissued today by Rhone-Poulenc Rorer Pharmaceuticals: Synercid(R) (quinupristin/dalfopristin) I.V., the firstinjectable antibiotic in a distinct class of antibacterials knownas streptogramins, was...
Zadavatel:
Chiron Receives Approval in France to Market Nucleic Acid Blood Tests For HIV-1 and HCV / First NAT Blood Tests Approved Worldwide
EMERYVILLE, Calif. (PROTEXT) - Chiron Corporation (Nasdaq:CHIR) today announced that it received approval from the FrenchMinistry of Health (AFSSAPS) to market to blood banks throughoutFrance its combination nucleic acid test (NAT) to simultaneouslydetect...
Zadavatel:
Genelabs Announces Positive Results of Pivotal Trial of Gl701 for Lupus / Company Intends to Submit New Drug Application to FDA
REDWOOD CITY, Calif. (PROTEXT) - Genelabs Technologies, Inc.(Nasdaq: GNLB) today announced positive results of its secondPhase III clinical trial of GL701, its investigational drug forsystemic lupus erythematosus (SLE). Based on the strength ofpreliminary...
Zadavatel:
Lowe & Partners a Lowe Healthcare Worldwide vytvořily společný podnik Lowe Consumer Healthcare
NEW YORK 21. září (PROTEXT/ots) - Lowe Healthcare Worldwide aLowe & Partners dnes oznámily, že vytvořily společný podnik,zaměřený na rychle se rozšiřující oblast marketingupředepisovaných léků přímo spotřebiteli (DTC) i na souvisejícílékařské a zdravotnické...
Zadavatel:
Na Ecco 10 předloženy údaje o stoupající míře přežití při léčbě pokročilé rakoviny prsu Herceptinem Herceptin také zlepšuje kvalitu života
VÍDEŇ 17. září (PROTEXT/ots) - Údaje, které byly předloženyna Evropské konferenci o rakovině ECCO 10, ukazují, žeHerceptin(R) (účinná látka: trastuzumab) je při léčení pokročilé(metastázující) rakoviny prsu silnou a účinnou protirakovinnoulátkou. Herceptin...
Zadavatel:
TAXOL(R)-Doxorubicin Combination Significantly Improves Survival In Metastatic Breast Cancer/ Large International Trial Defines Emerging First-Line Treatment St
Vienna, Austria (PROTEXT) - The anti-cancer drug TAXOL givenin combination with doxorubicin significantly prolongs mediantime to disease progression and survival in women with metastaticbreast cancer, according to results of a large Phase IIIinternational...
Zadavatel:
XTL Biopharmaceuticals and Eli Lilly & Company Enter Agreement To Evaluate Therapeutics For Hepatitis C - Testing Underway Utilizing Breakthrough Technique For
announced today an agreement to test an Eli Lilly & Company drugcandidate in XTL's proprietary animal model for hepatitis C. Theparties anticipate that XTL's technique could significantlyaccelerate the development and commercialization of...
Zadavatel:
New Study Indicates Benefits of Ampligen(R) In Treatment of Severe CFS
(Amex: HEB; HEBws) today announced results of an independentevaluation of the potential pharmaco-economic benefits ofAmpligen(R) in treatment of severe Chronic FatigueSyndrome/Myalgic Encephalomyelitis (CFS/ME), including a decreasein the number of doses...
Zadavatel:
Nová koncepce spolupráce v mezinárodním výzkumu rakoviny
mezi Rakouskem a východní Evropou, prezentovaná profesoremChristophem Zielinským v rámci CECOG (Central EuropeanCooperative Oncology Group) VÍDEŇ 8. září (PROTEXT/ots) - Před nedávnem byla vytvořenanová společná iniciativa mezi oblastí jihovýchodní a...
Zadavatel:
PPD GenuPro Announces Interim Analysis for Phase II
Genitourinary Compound / Collaboration Between PPD and Eli LillyProves Effective Wilmington, N.C. (PROTEXT) - PPD, Inc. (Nasdaq: PPDI) todayreported on the progress of its virtual drug development servicessubsidiary, PPD GenuPro, Inc. GenuPro was established...
Zadavatel: